SINGAPORE-- Takeda Pharmaceutical has identified a handful of Indian vaccinemakers as targets for M&A or other deal structures as it gets ready to take a plunge into a market that saw rival Daiichi Sankyo find nothing but trouble, according to sources that have spoken to executives at the Japanese company.
Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday.
Oncology biotech Mersana Therapeutics has expanded its relationship with Takeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.
In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution.
The new president at Takeda has raided Sanofi for its new head of global R&D. And they're putting their new top scientist in Cambridge, MA, which is becoming the world headquarters of drug research for much of the pharma industry.
Takeda, in the process of trimming down its R&D efforts, has inked a collaborative research deal with Australia's Monash University to discover and develop new treatments for gastrointestinal diseases.
So long, Millennium. Takeda, which shelled out $8.8 billion for the Massachusetts company back in 2008, is retiring what at one time was an iconic biotech brand.
In 2008, Takeda made waves in the biotech world when it agreed to pay $8.8 billion for Millennium Pharmaceuticals, a trailblazing outfit from Cambridge, MA. Now, years into integrating its acquisition, Takeda is dropping the Millennium moniker, spelling the end of the line for what was once an iconic brand in biotech.
The FDA has branded Takeda's top late-stage drug prospect--ixazomib (MLN9708), a multiple myeloma treatment designed to succeed the top-selling blockbuster Velcade--as a "breakthrough" therapy deserving VIP status with regulators.
When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers.